ClinicalTrials.gg
CompletedNCT01545765Updated Sep 2, 2021Results posted

Anesthetic Effect Duration Assessment

A Phase 4 interventional study of Lidocaine 7% + Tetracaine 7% cream in Healthy Volunteers, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-02.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the duration of anesthetic effect produced , Lidocaine7% + Tetracaine 7% cream when applied with 2 different application times on the face and thigh.

Read the detailed description

Subjects will have 4 target zones defined; 2 on the face and 2 on the anterior thighs. Upon inclusion into the study, subjects will have the study drug applied with a different application time to one side of the face and anterior thigh according to the randomization. After the completion of the application process, study drug on both sides of the face and on both anterior thighs will be removed by peeling.

After drug removal, the duration of anesthetic effect of the study drug will be tested using a pinprick test. Five (5) pinpricks using a 21-gauge needle will be performed at the 4 target zones (each side of the face and both anterior thighs). The pinprick test will be repeated up to 8 hours after drug removal. There will be a total of 20 post drug removal pinprick test completed.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
03

In context

Lead sponsor

Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male of female subjects aged 18 or older with a normal not excessive hairy skin,

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant or breast-feeding; or plan to become pregnant,
  • Subjects who have a known allergy to one of the components of the test drug lidocaine, tetracaine or other local anesthetics,
  • Subjects who are at risk in terms of precautions, warnings, and with the study product.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    lidocaine 7% and tetracaine 7%

    Drug: Lidocaine 7% + Tetracaine 7% cream

Interventions

  • DrugLidocaine 7% + Tetracaine 7% cream

    Drug page: Lidocaine

    Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.

06

What researchers measure

Primary outcomes

  1. Duration of Anesthesia(Minutes)

    Onset and end of anesthesia are evaluated by Pinprick tests. Duration of anesthesia is calculated as: difference between onset and end of anesthesia (minutes).

    Time frame: From T0 (product removal) up to T8 hours after product removal

Secondary outcomes

  1. Adverse Events

    Incidence of adverse events was to be reported during the study period

    Time frame: During the study

07

Results

Posted Sep 4, 2013
Limitations and caveats
No limitation or caveat on this study

Participant flow

31 healthy volunteers have been enrolled in one Phase I center at USA.First subject in: May 3d 2012; Last subject ou: May 26th 2012.

Participant flow — Overall Study
MilestoneFace 2 Application Times/ Thight 2 Application Times
Started31
Completed31
Not completed0

Outcome measures

SecondaryAdverse Events

Incidence of adverse events was to be reported during the study period

Time frame:
During the study
Reported as:
Number · participants
Adverse Events
participantsLidocaine 7% + Tetracaine 7% Face - First Application TimeLidocaine 7% + Tetracaine 7% Face - Second Application TimeLidocaine 7% + Tetracaine 7% Thigh - First Application TimeLidocaine 7% + Tetracaine 7% Thigh - Second Application Time
Adverse Events2222
PrimaryDuration of Anesthesia(Minutes)

Onset and end of anesthesia are evaluated by Pinprick tests. Duration of anesthesia is calculated as: difference between onset and end of anesthesia (minutes).

Time frame:
From T0 (product removal) up to T8 hours after product removal
Reported as:
Median · Minutes
Duration of Anesthesia(Minutes)
MinutesLidocaine 7% + Tetracaine 7% Face - First Application TimeLidocaine 7% + Tetracaine 7% Face - Second Application TimeLidocaine 7% + Tetracaine 7% Thigh - First Application TimeLidocaine 7% + Tetracaine 7% Thigh - Second Application Time
Duration of Anesthesia(Minutes)80 (0 to 420)140 (0 to 480)0 (0 to 460)400 (0 to 480)

Adverse events

Collected over All study period (from Baseline to end of teh study). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lidocaine 7% + Tetracaine 7%—0/31 (0%)2/31 (6.5%)
Most frequent other events
Most frequent other events
EventLidocaine 7% + Tetracaine 7%
SINUS HEADACHENervous system disorders1/31
HEADACHENervous system disorders1/31
DIZZINESSNervous system disorders1/31

Baseline characteristics

No sample size determination as a standard sample size for this type of study is about 30 subjects.

Age, Categorical
Age, Categorical(Participants)Lidocaine 7% and Tetracaine 7%
<=18 years0
Between 18 and 65 years29
>=65 years2
Age, Continuous
Age, Continuous(years)Lidocaine 7% and Tetracaine 7%
Mean47.2 ± 1.27
Sex: Female, Male
Sex: Female, Male(Participants)Lidocaine 7% and Tetracaine 7%
Female20
Male11
Region of Enrollment
Region of Enrollment(participants)Lidocaine 7% and Tetracaine 7%
United States31
08

Study locations

1 site
  • Galderma Investigational center
    Rochelle Park, New Jersey, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2012
First posted
Mar 7, 2012
Start
May 2012
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Sep 4, 2013
Last update
Sep 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01545765
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Mar 7, 2012
Start date
May 2012
Primary completion
May 2012
Completion
May 2012
Results posted
Sep 4, 2013
Last update
Sep 2, 2021

Study contacts

Regina YAVEL, MD- Dermatologist
principal investigator · Galderma investigational center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion